Loading
A phase 1/2 trial of Directional Brachytherapy Source Implant in pancreatic ductal adenocarcinoma, run by CivaTech Oncology, now recruiting.
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source is a phase 1/2 interventional study registered as NCT02843945 by CivaTech Oncology, with 80 participants planned, started 2017-05-31 and due to reach its primary completion in 2027-10-29. Interventions recorded: Directional Brachytherapy Source Implant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CivaTech Oncology and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/